Publications

Detailed Information

호르몬 수용체 면역조직화학염색 검사법의 검사실 간 차이에 대한 다기관 연구 : A Multi-institutional Study of Interlaboratory Variance in the Estrogen and Progesterone Receptor Assays

DC Field Value Language
dc.contributor.author이아원-
dc.contributor.author공경엽-
dc.contributor.author박경미-
dc.contributor.author박인애-
dc.contributor.author정우희-
dc.contributor.author이동화-
dc.date.accessioned2012-05-31T07:56:31Z-
dc.date.available2012-05-31T07:56:31Z-
dc.date.issued2010-03-
dc.identifier.citationJOURNAL OF BREAST CANCER; Vol.13 1; 46-52ko_KR
dc.identifier.issn1738-6756-
dc.identifier.urihttps://hdl.handle.net/10371/76703-
dc.description.abstractPurpose The expression of hormone receptors is the most reliable factor for predicting the responsiveness to hormonal therapy At present, immunohistochemistry (IHC) is considered as a practically reliable method. This study was designed to examine the interlaboratory variance in immunohistochemical assays for estrogen receptor (ER) and progesterone receptor (PR) in Korea Methods The Korean Study Group for Breast Pathology (KSGBP) made a questionnaire to know the current situation in HR assay in Korea. The questionnaire was sent to the members of KSGBP by e-mail, which were included eight questions relating to tissue handling, ER/PR IHC procedure and interpretation method. Forty laboratories replied with the completed questionnaire Results All 40 laboratories were using formalin as a fixative. Pretreatment was performed using six different methods including autoclave (25%), microwave (30%) and full autostainer (15%). Primary antibodies for ER were SP1 in 40%, 6F11 in 27.5% and 1D5 in 32.5%. Primary antibodies for PR were more variable (seven clones) than those for ER Interpretation method used was Allred system in 20%, modified Allred system in 15%, report the % of positive tumor cells in 45%, positive/negative in 15% and others in 5% The expression rate of ER was ranged from 45.6% to 93% (mean 635%) and the expression rate of PR was ranged from 27% to 90% (mean 59 1%) The differences according to the numbers of breast cancer in each institute, primary antibodies, detection systems and interpretation methods did not influence to the expression rate of ER/PR, statistically (p>0 05) Conclusion In Korea, the interlaboratory variance in ER/PR IHC procedure was too huge to make a standardized method We suggest the proper quality control program such as ER/PR staining with positive internal and external controls and negative control might be better to aim at getting similar results among the different laboratones rather than trying to standardize the procedure.ko_KR
dc.language.isokoko_KR
dc.publisherKOREAN BREAST CANCER SOCko_KR
dc.subjectEstrogen receptorsko_KR
dc.subjectQuestionnaireko_KR
dc.subjectImmunohistochemistryko_KR
dc.subjectProgesterone receptorsko_KR
dc.subject에스트로겐수용체ko_KR
dc.subject면역조직화학염색ko_KR
dc.subject프로게스테론수용체ko_KR
dc.subject설문조사ko_KR
dc.title호르몬 수용체 면역조직화학염색 검사법의 검사실 간 차이에 대한 다기관 연구ko_KR
dc.title.alternativeA Multi-institutional Study of Interlaboratory Variance in the Estrogen and Progesterone Receptor Assaysko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthorLee, Ahwon-
dc.contributor.AlternativeAuthorGong, Gyungyub-
dc.contributor.AlternativeAuthorPark, Kyeongmee-
dc.contributor.AlternativeAuthorPark, In Ae-
dc.contributor.AlternativeAuthorLee, Dong Wha-
dc.contributor.AlternativeAuthorJung, Woo Hee-
dc.identifier.doi10.4048/jbc.2010.13.1.46-
dc.citation.journaltitleJOURNAL OF BREAST CANCER-
dc.description.citedreferenceYun YH, 2007, BREAST CANCER RES TR, V106, P245, DOI 10.1007/s10549-006-9490-7-
dc.description.citedreferenceUMEMURA S, 2006, BREAST CANC, V13, P232-
dc.description.citedreferenceJOO HJ, 2006, MANUAL QUALITY CONTR, P139-
dc.description.citedreferenceGoldhirsch A, 2005, ANN ONCOL, V16, P1569, DOI 10.1093/annonc/mdi326-
dc.description.citedreferenceMann GB, 2005, J CLIN ONCOL, V23, P5148, DOI 10.1200/JCO.2005.02.076-
dc.description.citedreferenceRudiger T, 2002, AM J SURG PATHOL, V26, P873-
dc.description.citedreferenceRhodes A, 2001, AM J CLIN PATHOL, V115, P44-
dc.description.citedreferenceFitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966-
dc.description.citedreferenceRhodes A, 2000, J CLIN PATHOL, V53, P292-
dc.description.citedreferenceRhodes A, 2000, J CLIN PATHOL, V53, P125-
dc.description.citedreferenceHarvey JM, 1999, J CLIN ONCOL, V17, P1474-
dc.description.citedreferenceTaylor CR, 1999, AM J CLIN PATHOL, V111, P443-
dc.description.citedreferenceBarnes DM, 1998, EUR J CANCER, V34, P1677-
dc.description.citedreferenceBarnes DM, 1996, BRIT J CANCER, V74, P1445-
dc.description.citedreferenceAlberts SR, 1996, CANCER, V78, P764-
dc.description.citedreferenceGREENE GL, 1982, J STEROID BIOCHEM, V16, P353-
dc.description.citedreferenceGREENE GL, 1980, P NATL ACAD SCI-BIOL, V77, P5115-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share